Universidade do Algarve | 12h30 | Auditorium 1.8.1
Title: “Polyglutamine diseases: learning from molecular pathogenesis to develop therapies”
Abstract: Polyglutamine (PolyQ) diseases are a group of nine rare and incurable neurodegenerative disorders caused by an abnormal expansion of the trinucleotide CAG in the causative gene, which encodes a PolyQ tract in their respective proteins. The abnormal proteins tend to aggregate, forming insoluble protein aggregates, which is a key feature of PolyQ diseases. These aggregates are in the basis of a cascade of events leading to neuronal degeneration and death, involving the impairment and dysregulation of several cell systems, including autophagy, proteostasis, transcription, mitochondrial function, and signalling. The accumulated knowledge on these mechanisms allowed a significant research effort into putative therapeutic approaches based in strategies that counteract disease at different stages of molecular pathogenesis. Our main goal is to develop advanced therapies systems based in gene therapy to PolyQ diseases while contributing to the understanding of the molecular events leading to neurodegeneration.
Short Bio: Clévio Nóbrega holds a position as an Assistant at the Department of Biomedical Sciences and Medicine (DCBM, University of Algarve) and Principal Investigator (PI) of the Centre for Biomedical Research (CBMR, University of Algarve). Clévio Nóbrega graduated in Biology from the University of Madeira in 2000 and completed a Ph.D. in Molecular Biology and Cytogenetics in 2007. Until now Clévio Nóbrega published 28 papers in international peer-review journals, in multidisciplinary journals like PLosOne, and in more specific journals like Brain or Molecular Biology and Evolution. Clévio Nóbrega is the editor of two scientific participative books from Springer, being also the author of 5 book chapters. Recently, he received the second prize Jansen innovation, the national award of the Portuguese Human Genetics Society 2016 and the European Society for Neurochemistry Young Scientist Lectureship Award 2017. As PI he received several research grants from the Portuguese Science Foundation, the National Ataxia Foundation, Ataxia UK and the French Muscular Dystrophy Association. Clévio Nóbrega is a member of the editorial board of the journals: Frontiers in Neurosciences and Medicine; participated as a reviewer in different scientific journals, and as an expert consultant in the evaluation of H2020 program proposals.